Common symptoms for Mpox include rash, fever, sore throat, headache, muscle aches, back pain, low energy, and swollen lymph nodes. Symptoms usually begin within a week but can start one to 21 days ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...

83% of participants on tecovirimat achieved clinical resolution, compared to 84% on placebo, which was not significantly different. Pain reduction was similar in both groups, with tecovirimat ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical ...

"The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox, ...

Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...

LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not ...

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...

Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.

While these studies did not show statistical significance difference between tecovirimat and placebo at this primary endpoint, the PALM 007 results did signal potential benefits for patients ...